PD-L1在非小细胞肺癌中表达的检测方法  

Detection methods of PD-L1 expression in non-small cell lung cancer

作　　者：钟国方(综述) 袁霞(审校)[1] ZHONG Guo-fang;YUAN Xia(Department of Oncology,Huizhou Central People’s Hospital,Huizhou 516000,China)

机构地区：[1]广东省惠州市中心人民医院肿瘤内科,广东惠州516000

出　　处：《广东医科大学学报》2021年第2期239-245,共7页Journal of Guangdong Medical University

基　　金：惠州市科技计划项目(No.2016C0405020)。

摘　　要：免疫检查点抑制剂(ICI)通过阻断程序性死亡受体-1(PD-1)及其配体(PD-L1),已成为非小细胞肺癌(NSCLC)的新型治疗策略,为晚期NSCLC的治疗带来了新希望。肿瘤细胞PD-L1表达可预测肺癌患者对ICI反应性,PD-L1已成为预测免疫治疗效果的生物标志物。本文拟综述NSCLC中PD-L1表达的检测方法。Immune checkpoint inhibitors have become a new treatment strategy for non-small cell lung cancer(NSCLC)by blocking programmed death receptor-1(PD-1)and its ligand PD-L1,which opens new expectation on advanced NSCLC.PD-L1 expression of tumor cells can predict the response of ICIs in lung cancer patients and serve as a biomarker for predicting the efficacy of immunotherapy.This article aims to review the detection methods of PD-L1 expression in NSCLC.

关 键 词：非小细胞肺癌 程序性死亡配体-1 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]